Investor Relations

Boston Therapeutics Completes Human Clinical Study with SUGARDOWN™ at University of Sydney

Download PDF

SUGARDOWN™ – A polysaccharide-hydrolyzing enzymes inhibitor

MANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN™, a dietary supplement designed to reduce post-meal elevation of blood glucose.

"We are very pleased to have completed this trial at the Sydney University Glycemic Index Research Service (SUGiRS), and delighted to have worked with Dr. Jennie Brand-Miller who conducted the trial,” said Ken Tassey, President at Boston Therapeutics. This study has important endpoints that support our expectation that SUGARDOWN™ can be a powerful tool for many people who struggle with blood sugar management.”

SUGARDOWN™ was tested in healthy, but overweight adults with a mean body mass index (BMI) value of 27.3 kg/m2. The data were collected for postprandial blood sugar elevation with a 50g glucose challenge.

“We are in the process of summarizing the data to demonstrate the significant reduction in postprandial blood glucose after consumption of SUGARDOWN™ chewable tablets,” said Joan Sellers, Ph.D., and company Chief Technology Officer.

About Sydney University GI Research Service (SUGiRS)

SUGiRS was established in 1995 by Dr. Jennie Brand-Miller to provide a reliable commercial GI testing laboratory for the local and international food industry. Foods are tested in healthy volunteers according to standardized methods that have been validated with laboratories around the world for Insulin, satiety, hunger and other parameters to be assessed simultaneously. Dr. Brand-Miller is Professor of Human Nutrition at the University of Sydney and top authority in carbohydrates and the glycemic index, and their role in human health. Her research interests focus on all aspects of carbohydrates including diabetes, insulin resistance, lactose intolerance and infant nutrition. Her book about the low Glycemic Index diet, The New Glucose Revolution, is an international best-seller. She has published 16 books and 220 journal articles.

About Glycemic Index

The glycemic index or GI is a measure of the effects of carbohydrates on blood sugar levels. Carbohydrates that break down quickly during digestion and release glucose rapidly into the bloodstream have a high GI; carbohydrates that break down more slowly, releasing glucose more gradually into the bloodstream, have a low GI. The concept was developed by Dr. David J. Jenkins and colleagues 1980–1981 at the University of Toronto in their research to find out which foods were best for people with diabetes.


SUGARDOWN™ is a complex carbohydrate-based dietary supplement to moderate post-meal blood glucose for pre-diabetes and those concerned about their blood glucose levels. It is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal system to block the action of carbohydrate-hydrolyzing enzymes which break down carbohydrates into glucose and release it into the bloodstream.

About Boston Therapeutics, Inc.

Boston Therapeutics is a leader in the field of glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: SUGARDOWN™, a complex carbohydrate-based dietary supplement designed to moderate post-meal blood glucose,, IPOXYNTM, an intravenous, oxygen therapeutic for limb ischemia and PAZ-320, a diabetes drug candidate to reduce postprandial glucose excursion. Earlier this year Boston Therapeutics signed a licensing agreement with Hong Kong-based Advance Pharmaceuticals Co Ltd. to market SUGARDOWN™ in China.

Boston Therapeutics is headquartered in Manchester, NH.

Additional information is available at

SUGARDOWN™ is a registered trademark of Boston Therapeutics, Inc.